Cinacalcet hydrochloride for the treatment of hyperparathyroidism
N Verheyen, S Pilz, K Eller, K Kienreich… - Expert opinion on …, 2013 - Taylor & Francis
Introduction: Effective therapeutic strategies are warranted to reduce the burden of
parathyroid hormone excess related morbidity and mortality. The calcimimetic agent …
parathyroid hormone excess related morbidity and mortality. The calcimimetic agent …
Treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)
H Komaba, M Tanaka, M Fukagawa - Internal Medicine, 2008 - jstage.jst.go.jp
Disturbances in mineral and bone metabolism play a critical role in the pathogenesis of
cardiovascular complications in patients with chronic kidney disease (CKD). The term “renal …
cardiovascular complications in patients with chronic kidney disease (CKD). The term “renal …
Cost-effectiveness of cinacalcet hydrochloride for hemodialysis patients with severe secondary hyperparathyroidism in Japan
H Komaba, K Moriwaki, S Goto, S Yamada… - American journal of …, 2012 - Elsevier
BACKGROUND: Cinacalcet effectively reduces elevated levels of parathyroid hormone
(PTH) in patients with secondary hyperparathyroidism (SHPT), even those with severe …
(PTH) in patients with secondary hyperparathyroidism (SHPT), even those with severe …
Health state utilities associated with major clinical events in the context of secondary hyperparathyroidism and chronic kidney disease requiring dialysis
EW Davies, LS Matza, G Worth, DH Feeny… - Health and Quality of …, 2015 - Springer
Background Patients with chronic kidney disease (CKD) and secondary
hyperparathyroidism (SHPT) who require dialysis are at increased risk for cardiovascular …
hyperparathyroidism (SHPT) who require dialysis are at increased risk for cardiovascular …
Future drug prices and cost-effectiveness analyses
M Hoyle - Pharmacoeconomics, 2008 - Springer
Background Cost-effectiveness analyses worldwide assume that the price of any single drug
increases with inflation. New guidance from the Pharmaceutical Management Agency in …
increases with inflation. New guidance from the Pharmaceutical Management Agency in …
An economic comparison of surgical and medical therapy in patients with secondary hyperparathyroidism—the German perspective
R Schneider, G Kolios, BM Koch, ED Fernández… - Surgery, 2010 - Elsevier
BACKGROUND: Treatment options for secondary hyperparathyroidism were significantly
amended with the introduction of cinacalcet and paricalcitol. Limitations of resources in …
amended with the introduction of cinacalcet and paricalcitol. Limitations of resources in …
[HTML][HTML] Calcimimetics in chronic kidney disease: evidence, opportunities and challenges
P Evenepoel - Kidney international, 2008 - Elsevier
Secondary hyperparathyroidism (SHPT) remains a highly prevalent and important
complication in patients with chronic kidney disease (CKD). Indeed, SHPT may compromise …
complication in patients with chronic kidney disease (CKD). Indeed, SHPT may compromise …
The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta …
D Li, L Shao, H Zhou, W Jiang, W Zhang, Y Xu - Endocrine, 2013 - Springer
Cinacalcet, the first calcimimetic to be approved for the treatment of secondary
hyperparathyroidism (SHPT) in the chronic kidney disease patients, offers a novel …
hyperparathyroidism (SHPT) in the chronic kidney disease patients, offers a novel …
Cinacalcet: pharmacological and clinical aspects
The calcium sensing receptor (CaSR) is expressed in cells secreting calcium-regulating
hormones, in cells involved in calcium transport and in many other tissues, with an as yet not …
hormones, in cells involved in calcium transport and in many other tissues, with an as yet not …
Pharmacological management of secondary hyperparathyroidism in patients with chronic kidney disease
SN Salam, A Khwaja, ME Wilkie - Drugs, 2016 - Springer
Secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney
disease (CKD) and is part of the CKD-mineral bone disorder (CKD-MBD). SHPT is …
disease (CKD) and is part of the CKD-mineral bone disorder (CKD-MBD). SHPT is …